← Leaderboards
Sumithira Vasu
Ohio State University
$6,137,636
Attributed
$7,335,873
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,335,873 · 3
By mechanism
R01$5,568,705 · 2
UG1$1,767,168 · 1
Top collaborators
- Lapo Alinari3 shared
- Marcos De Lima3 shared
Most similar at Ohio State University
Same institution · by research overlap
- Susan R Mallery$15,292,540
- Michael C Ostrowski$13,472,116
- Jeffrey John Chalmers$7,748,895
- Elliott D Crouser$4,838,276
- Lapo Alinari$4,506,413
Others in their field
Other Emerging Leaders on “Ohio”
- Stephen F Kry · University Of Tx Md Anderson Can Ctr$29,134,773
- Jeremy James Martinson · University Of Pittsburgh At Pittsburgh$17,639,647
- Robert Wilson Frenck · Cincinnati Childrens Hosp Med Ctr$16,660,001
- Anil V Parwani · Ohio State University$6,050,541
- Jessie P Buckley · Johns Hopkins University$5,118,404
- Aaron Thomas Gerds · Case Western Reserve University$4,919,992
Research focus
OhioUniversitiesCellsHigh RiskPhenotypeToxic EffectAdultOlder PatientRelapseReportingInfectionImmuneSafetyBloodSuccessNovel StrategiesFutureTransplantationTransplant RecipientsAllogenicIncidenceCell TherapyT-LymphocyteGraft Vs Host Disease
Grant awards (17)
Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies$609,273
R01 · FY2025 · CA · contact PI
BMT Core- The Ohio State University blood and marrow transplant research consortium$233,355
UG1 · FY2025 · HL · contact PI
MIDAS: MIcroangiopathy, endothelial Damage in Adults undergoing Stem cell transplantation$728,230
R01 · FY2024 · HL · contact PI
Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies$578,809
R01 · FY2024 · CA · contact PI
BMT Core- The Ohio State University blood and marrow transplant research consortium$262,868
UG1 · FY2024 · HL · contact PI
MIDAS: MIcroangiopathy, endothelial Damage in Adults undergoing Stem cell transplantation$743,092
R01 · FY2023 · HL · contact PI
Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies$609,273
R01 · FY2023 · CA · contact PI
The Ohio State University Blood and Marrow Transplant Research Consortium$173,511
UG1 · FY2023 · HL · contact PI
MIDAS: MIcroangiopathy, endothelial Damage in Adults undergoing Stem cell transplantation$743,092
R01 · FY2022 · HL · contact PI
The Ohio State University Blood and Marrow Transplant Research Consortium$175,490
UG1 · FY2022 · HL · contact PI
MIDAS: MIcroangiopathy, endothelial Damage in Adults undergoing Stem cell transplantation$743,092
R01 · FY2021 · HL · contact PI
The Ohio State University Blood and Marrow Transplant Research Consortium$177,249
UG1 · FY2021 · HL · contact PI
MIDAS: MIcroangiopathy, endothelial Damage in Adults undergoing Stem cell transplantation$813,844
R01 · FY2020 · HL · contact PI
The Ohio State University Blood and Marrow Transplant Research Consortium$179,429
UG1 · FY2020 · HL · contact PI
The Ohio State University Blood and Marrow Transplant Research Consortium$181,553
UG1 · FY2019 · HL · contact PI
The Ohio State University Blood and Marrow Transplant Research Consortium$189,704
UG1 · FY2018 · HL · contact PI
The Ohio State University Blood and Marrow Transplant Research Consortium$194,009
UG1 · FY2017 · HL · contact PI